We use cookies to improve your experience. By continuing to browse this site, you accept our cookie policy.×
Skip main navigation
Open Drawer MenuClose Drawer Menu
Aging Health
Bioelectronics in Medicine
Biomarkers in Medicine
Breast Cancer Management
CNS Oncology
Colorectal Cancer
Concussion
Epigenomics
Future Cardiology
Future Medicine AI
Future Microbiology
Future Neurology
Future Oncology
Future Rare Diseases
Future Virology
Hepatic Oncology
HIV Therapy
Immunotherapy
International Journal of Endocrine Oncology
International Journal of Hematologic Oncology
Journal of 3D Printing in Medicine
Lung Cancer Management
Melanoma Management
Nanomedicine
Neurodegenerative Disease Management
Pain Management
Pediatric Health
Personalized Medicine
Pharmacogenomics
Regenerative Medicine
Preliminary Communication

Recombinant human FGF-2 therapy for osteonecrosis of the femoral head: 5-year follow-up

    Yutaka Kuroda

    *Author for correspondence: Tel.: +81 75 751 3370;

    E-mail Address: ykuromd@kuhp.kyoto-u.ac.jp

    Department of Orthopaedic Surgery, Graduate School of Medicine, Kyoto University, Shogoin, Kawahara-cho 54, Sakyo-ku, Kyoto 606-8507, Japan

    Search for more papers by this author

    ,
    Toshiko Ito-Ihara

    Department of Clinical Innovative Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan

    Search for more papers by this author

    ,
    Hiroyasu Abe

    Department of Biomedical Statistics & Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan

    Search for more papers by this author

    ,
    Manabu Nankaku

    Rehabilitation Unit, Kyoto University Hospital, Kyoto, Japan

    Search for more papers by this author

    ,
    Yaichiro Okuzu

    Department of Orthopaedic Surgery, Graduate School of Medicine, Kyoto University, Shogoin, Kawahara-cho 54, Sakyo-ku, Kyoto 606-8507, Japan

    Search for more papers by this author

    ,
    Toshiyuki Kawai

    Department of Orthopaedic Surgery, Graduate School of Medicine, Kyoto University, Shogoin, Kawahara-cho 54, Sakyo-ku, Kyoto 606-8507, Japan

    Search for more papers by this author

    ,
    Koji Goto

    Department of Orthopaedic Surgery, Graduate School of Medicine, Kyoto University, Shogoin, Kawahara-cho 54, Sakyo-ku, Kyoto 606-8507, Japan

    Search for more papers by this author

    &
    Shuichi Matsuda

    Department of Orthopaedic Surgery, Graduate School of Medicine, Kyoto University, Shogoin, Kawahara-cho 54, Sakyo-ku, Kyoto 606-8507, Japan

    Search for more papers by this author

    Published Online:1 Dec 2020https://doi.org/10.2217/rme-2020-0148

    Abstract

    Aim: To evaluate the 5-year outcomes from the prospective study of recombinant human FGF-2 (rhFGF-2) for osteonecrosis of the femoral head (ONFH). Methods: Ten patients (average age 39.8 years) with nontraumatic, precollapse ONFH were percutaneously administered with 800 μg rhFGF-2 contained in gelatin hydrogel. Radiological changes and the prevalidated Harris hip score (HHS), visual analogue scale for pain and University of California, Los Angeles activity-rating scale scoring systems were evaluated. Results: The 5-year comparison in type C2 showed higher joint preservation in the rhFGF-2 group (71.4%) than in the natural course group (15.4%). Two of three clinical scores (Harris hip score and visual analogue scale for pain) improved significantly. Postoperative MRI demonstrated significant reduction in ONFH size. There were no adverse events. Conclusion: rhFGF-2 treatment for ONFH appears to be safe and effective and may have the potential to prevent disease progression.

    Papers of special note have been highlighted as: • of interest; •• of considerable interest

    References

    • 1. Petek D, Hannouche D, Suva D. Osteonecrosis of the femoral head: pathophysiology and current concepts of treatment. EFORT Open Rev. 4(3), 85–97 (2019).
      MedlineGoogle Scholar
    • 2. Mont MA, Salem HS, Piuzzi NS, Goodman SB, Jones LC. Nontraumatic osteonecrosis of the femoral head: where do we stand today? A 5-year update. J. Bone Joint Surg. Am. 102(12), 1084–1099 (2020). •• A useful overview of nontraumatic osteonecrosis of the femoral head.
      MedlineGoogle Scholar
    • 3. Moya-Angeler J, Gianakos AL, Villa JC, Ni A, Lane JM. Current concepts on osteonecrosis of the femoral head. World J. Orthop. 6(8), 590–601 (2015). • A detailed current concept of nontraumatic osteonecrosis of the femoral head.
      MedlineGoogle Scholar
    • 4. Larson E, Jones LC, Goodman SB, Koo KH, Cui Q. Early-stage osteonecrosis of the femoral head: where are we and where are we going in year 2018? Int. Orthop. 42(7), 1723–1728 (2018).
      MedlineGoogle Scholar
    • 5. Chughtai M, Piuzzi NS, Khlopas A, Jones LC, Goodman SB, Mont MA. An evidence-based guide to the treatment of osteonecrosis of the femoral head. Bone Joint J. 99-B(10), 1267–1279 (2017).
      Medline CASGoogle Scholar
    • 6. Hernigou P, Poignard A, Zilber S, Rouard H. Cell therapy of hip osteonecrosis with autologous bone marrow grafting. Indian J. Orthop. 43(1), 40–45 (2009).
      MedlineGoogle Scholar
    • 7. Wang BL, Sun W, Shi ZC et al. Treatment of nontraumatic osteonecrosis of the femoral head with the implantation of core decompression and concentrated autologous bone marrow containing mononuclear cells. Arch. Orthop. Trauma Surg. 130(7), 859–865 (2010).
      MedlineGoogle Scholar
    • 8. Yamasaki T, Yasunaga Y, Ishikawa M, Hamaki T, Ochi M. Bone-marrow-derived mononuclear cells with a porous hydroxyapatite scaffold for the treatment of osteonecrosis of the femoral head: a preliminary study. J. Bone Joint Surg. Br. 92(3), 337–341 (2020).
      Google Scholar
    • 9. Gangji V, De Maertelaer V, Hauzeur JP. Autologous bone marrow cell implantation in the treatment of non-traumatic osteonecrosis of the femoral head: five year follow-up of a prospective controlled study. Bone 49(5), 1005–1009 (2011).
      MedlineGoogle Scholar
    • 10. Sen RK, Tripathy SK, Aggarwal S, Marwaha N, Sharma RR, Khandelwal N. Early results of core decompression and autologous bone marrow mononuclear cells instillation in femoral head osteonecrosis: a randomized control study. J. Arthroplasty 27(5), 679–686 (2012).
      MedlineGoogle Scholar
    • 11. Zhao D, Cui D, Wang B et al. Treatment of early stage osteonecrosis of the femoral head with autologous implantation of bone marrow-derived and cultured mesenchymal stem cells. Bone 50(1), 325–330 (2012).
      MedlineGoogle Scholar
    • 12. Martin JR, Houdek MT, Sierra RJ. Use of concentrated bone marrow aspirate and platelet-rich plasma during minimally invasive decompression of the femoral head in the treatment of osteonecrosis. Croat. Med. J. 54(3), 219–224 (2013).
      MedlineGoogle Scholar
    • 13. Cruz-Pardos A, Garcia-Rey E, Ortega-Chamarro JA, Duran-Manrique D, Gomez-Barrena E. Mid-term comparative outcomes of autologous bone-marrow concentration to treat osteonecrosis of the femoral head in standard practice. Hip Int. 26(5), 432–437 (2016).
      MedlineGoogle Scholar
    • 14. Tomaru Y, Yoshioka T, Sugaya H et al. Ten-year results of concentrated autologous bone marrow aspirate transplantation for osteonecrosis of the femoral head: a retrospective study. BMC Musculoskelet. Disord. 20(1), 410 (2019).
      MedlineGoogle Scholar
    • 15. Houdek MT, Wyles CC, Martin JR, Sierra RJ. Stem cell treatment for avascular necrosis of the femoral head: current perspectives. Stem Cells Cloning 7, 65–70 (2014). • A detailed review of the clinical application of stem cell therapies in avascular necrosis of the femoral head.
      MedlineGoogle Scholar
    • 16. Landgraeber S, Warwas S, Claßen T, Jäger M. Modifications to advanced core decompression for treatment of avascular necrosis of the femoral head. BMC Musculoskelet. Disord. 18(1), 479 (2017).
      MedlineGoogle Scholar
    • 17. Lieberman JR, Conduah A, Urist MR. Treatment of osteonecrosis of the femoral head with core decompression and human bone morphogenetic protein. Clin. Orthop. Relat. Res. 429, 139–145 (2004).
      Google Scholar
    • 18. Seyler TM, Marker DR, Ulrich SD, Fatscher T, Mont MA. Nonvascularized bone grafting defers joint arthroplasty in hip osteonecrosis. Clin. Orthop. Relat. Res. 466(5), 1125–1132 (2008).
      MedlineGoogle Scholar
    • 19. Papanagiotou M, Malizos KN, Vlychou M, Dailiana ZH. Autologous (non-vascularised) fibular grafting with recombinant bone morphogenetic protein-7 for the treatment of femoral head osteonecrosis: preliminary report. Bone Joint J. 96-B(1), 31–35 (2014).
      Medline CASGoogle Scholar
    • 20. Kuroda Y, Tanaka T, Miyagawa T et al. A pilot study of regenerative therapy using controlled release of rhFGF-2 for patients with pre-collapse osteonecrosis of the femoral head. Int. Orthop. 40(8), 1747–1754 (2016).
      MedlineGoogle Scholar
    • 21. Kuroda Y, Akiyama H, Kawanabe K, Tabata Y, Nakamura T. Treatment of experimental osteonecrosis of the hip in adult rabbits with a single local injection of recombinant human FGF-2 microspheres. J. Bone. Miner. Metab. 28(6), 608–616 (2010).
      Medline CASGoogle Scholar
    • 22. Sugano N, Atsumi T, Ohzono K, Kubo T, Hotokebuchi T, Takaoka K. The 2001 revised criteria for diagnosis, classification, and staging of idiopathic osteonecrosis of the femoral head. J. Orthop. Sci. 7(5), 601–605 (2002).
      MedlineGoogle Scholar
    • 23. Kuroda Y, Tanaka T, Miyagawa T et al. Classification of osteonecrosis of the femoral head: who should have surgery? Bone Joint Res. 8(10), 451–458 (2019). •• Provided the collapse rate of the femoral head in the patients with osteonecrosis of the femoral head.
      Medline CASGoogle Scholar
    • 24. Amstutz HC, Thomas BJ, Jinnah R, Kim W, Grogan T, Yale C. Treatment of primary osteoarthritis of the hip. A comparison of total joint and surface replacement arthroplasty. J. Bone Joint Surg. Am. 66(2), 228–241 (1984).
      Medline CASGoogle Scholar
    • 25. Harris WH. Traumatic arthritis of the hip after dislocation and acetabular fractures: treatment by mold arthroplasty. An end-result study using a new method of result evaluation. J. Bone Joint Surg. Am. 51(4), 737–755 (1969).
      Medline CASGoogle Scholar
    • 26. Houdek MT, Wyles CC, Packard BD, Terzic A, Behfar A, Sierra RJ. Decreased osteogenic activity of mesenchymal stem cells in patients with corticosteroid-induced osteonecrosis of the femoral head. J. Arthroplasty 31(4), 893–838 (2016).
      MedlineGoogle Scholar
    • 27. Tabata Y, Miyao M, Yamamoto M, Ikada Y. Vascularization into a porous sponge by sustained release of basic fibroblast growth factor. J. Biomater. Sci. Polym. Ed. 10(9), 957–968 (1999).
      Medline CASGoogle Scholar
    • 28. Kuroda Y, Kawai T, Goto K. Matsuda S. Clinical application of injectable growth factor for bone regeneration: a systematic review. Inflamm. Regener. 39, 20 (2019). • Illustrates current regenerative therapy in osteonecrosis of the femoral head.
      MedlineGoogle Scholar
    • 29. D'Ambrosi R, Biancardi E, Massari G, Ragone V, Facchini RM. Survival analysis after core decompression in association with platelet-rich plasma, mesenchymal stem cells, and synthetic bone graft in patients with osteonecrosis of the femoral head. Joints 6(1), 16–22 (2018).
      MedlineGoogle Scholar
    • 30. Kawaguchi H, Oka H, Jingushi S et al. A local application of recombinant human fibroblast growth factor 2 for tibial shaft fractures: a randomized, placebo-controlled trial. J. Bone Miner. Res. 26(2), 2735–2743 (2010). •• A prospective randomized controlled trial using FGF-2 in tibial fractures, demonstrating that FGF-2 use led to early bone healing.
      Google Scholar
    • 31. Kawaguchi H, Jingushi S, Izumi T et al. Local application of recombinant human fibroblast growth factor-2 on bone repair: a dose-escalation prospective trial on patients with osteotomy. J. Orthop. Res. 25(4), 480–487 (2007).
      Medline CASGoogle Scholar